The FDA user fee law may end up serving as a catalyst not only for the development of new antibiotics, but also for the agency’s revamping of its drug approval processes for anti-infective drugs.
A mix of new incentives specifically geared for antibiotics, such as additional marketing exclusivity and guidance on streamlining the drug...